Analyst Ratings For Avid Bioservices Inc (NASDAQ:CDMO)
Today, HC Wainwright reiterated its Buy rating on Avid Bioservices Inc (NASDAQ:CDMO) with a price target of $11.00.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Avid Bioservices Inc (NASDAQ:CDMO) is Buy with a consensus target price of $8.75 per share, a potential 22.04% upside.
Some recent analyst ratings include
- 9/11/2018-Avid Bioservices Inc (NASDAQ:CDMO) had its Buy rating reiterated by HC Wainwright with a $11.00 price target
- 6/25/2018-Avid Bioservices Inc (NASDAQ:CDMO) has coverage initiated with a Buy rating and $10.00 price target
- 3/15/2018-Avid Bioservices Inc (NASDAQ:CDMO) has coverage initiated with a Outperform rating
- 3/13/2018-Avid Bioservices Inc (NASDAQ:CDMO) has coverage initiated with a Overweight rating and $4.00 price target
- 1/5/2018-Avid Bioservices Inc (NASDAQ:CDMO) had its Buy rating reiterated by Noble Financial
- 9/13/2016-Avid Bioservices Inc (NASDAQ:CDMO) had its Neutral rating reiterated by Roth Capital with a $3.50 price target
- 9/12/2016-Avid Bioservices Inc (NASDAQ:CDMO) had its Outperform rating reiterated by FBR & Co with a $7.00 price target
Recent Insider Trading Activity For Avid Bioservices Inc (NASDAQ:CDMO)
Avid Bioservices Inc (NASDAQ:CDMO) has insider ownership of 0.92% and institutional ownership of 21.72%.
- On 2/15/2018 Mark R Bamforth, Director, bought 50,000 with an average share price of $2.25 per share and the total transaction amounting to $112,500.00.
About Avid Bioservices Inc (NASDAQ:CDMO)
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Recent Trading Activity for Avid Bioservices Inc (NASDAQ:CDMO)
Shares of Avid Bioservices Inc closed the previous trading session at 7,17 +0,050 0,70 % with 6.92 shares trading hands.
